Active Ingredient History
Givinostat, sold under the brand name Duvyzat is a medication used for the treatment of Duchenne muscular dystrophy. It is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominoplasty (Phase 2)
Arthritis, Juvenile (Phase 2)
Crohn Disease (Phase 1/Phase 2)
Drug Interactions (Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Immunoglobulin D (Phase 2)
Inflammation (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Multiple Myeloma (Phase 2)
Muscular Dystrophy, Duchenne (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasms ()
Polycythemia Vera (Phase 3)
Receptors, Tumor Necrosis Factor (Phase 2)
Schnitzler Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue